Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 107

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Cerebrovascular accident+1

Not recruiting

Study on the Effectiveness of Alteplase as an Add-On to Mechanical Thrombectomy for Patients with Acute Ischemic Stroke

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer

Cerebral palsy+5

Not recruiting

Study on Valbenazine for Treating Dyskinesia in Children and Adults with Cerebral Palsy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Valbenazine Ditosylate
  • Sponsor:Neurocrine Biosciences Inc.

Glycogen storage disease type II

Not recruiting

Study on the Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Children with Late-onset Pompe Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cipaglucosidase Alfa
  • Sponsor:Amicus Therapeutics Inc.

Central nervous system lymphoma

Not recruiting

Study on Methotrexate, Tafasitamab, Lenalidomide, and Rituximab for Patients with Primary Central Nervous System Lymphoma Not Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:University Of Cologne

Spinal cord injury cervical

Not recruiting

Study on the Safety and Effectiveness of Elezanumab for Adults with Acute Traumatic Cervical Spinal Cord Injury

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elezanumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neuromuscular blockade

Not recruiting

Study on the Effectiveness of Dexmedetomidine, Ropivacaine, and Dexamethasone for Pain Relief in Patients Undergoing Shoulder Surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Algemeen ziekenhuis Rivierenland

Muscular dystrophy

Not recruiting

Gene Therapy Study for Patients with Limb-Girdle Muscular Dystrophy Using GNT0006

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Atamyo Therapeutics

Spinal muscular atrophy

Not recruiting

Study of Risdiplam for Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Risdiplam
  • Sponsor:F. Hoffmann-La Roche AG

Severe myoclonic epilepsy of infancy+1

Not recruiting

Study on Soticlestat for Children and Adults with Dravet or Lennox-Gastaut Syndrome Previously Treated with Fenfluramine

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Soticlestat
  • Sponsor:Takeda Development Center Americas Inc.

Narcolepsy

Not recruiting

Study on Blood Pressure Changes in Narcolepsy Patients Switching from High-Sodium Oxybate to JZP258 (Oxybate Mixed-Salt Formulation)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Oxybate
  • Sponsor:Jazz Pharmaceuticals PLC

Dementia of the Alzheimer's type uncomplicated

Not recruiting

Study of XPro1595 for Patients with Early Alzheimer's Disease and Inflammation Markers

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pegipanermin
  • Sponsor:Inmune Bio Inc.

Dementia Alzheimer's type

Not recruiting

Study on the Effects of Semaglutide on Inflammation in Patients with Alzheimer's Disease

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.